We were delighted to speak with Dr Noa Krugliak Cleveland M.D. (University of Chicago, Chicago, IL, USA) around her talk on the RALEE study, investigating the impact of early initiation of vedolizumab in UC.
The abstract ‘EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)’ which was presented at the virtual 2022 Crohn’s & Colitis Congress, 20-22 January, 2022.
- What is known about the effect of timing of initiation of biologic therapies in ulcerative colitis? (0:10)
- What were the aims and design of the RALEE study? (0:58)
- What did the study tell us about patient characteristics and treatment patterns? (1:28)
- What can be done to ensure treatment patterns more closely match the guidelines? (2:13)
Disclosures: Noa Krugliak Cleveland discloses consulting for Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual Crohn’s & Colitis Congress 2022.
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!